Clinical Trials Sponsored by Allderma Pharmaceuticals

Total 19957 results

Galderma R&D

Completed

ORCA - Oracea® for Rosacea: A Community-based Assessment

Rosacea

United States
Galderma R&D

Completed

Tolerability Comparison Between Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin

Skin Manifestations

United States
Galderma R&D

Completed

Study to Evaluate Restylane Vital Light Using an Injector Device

Aesthetics

Germany
Galderma R&D

Completed

Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis

Psoriasis

United States
Galderma R&D

Completed

Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis

Plaque Psoriasis

United States
Galderma R&D

Completed

Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea

Papulopustular Rosacea

United States
Galderma R&D

Completed

Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis

Psoriasis

United States, Canada
Galderma R&D

Completed

A Treatment Regimen for Student Athletes With Mild to Moderate Acne Vulgaris

Acne Vulgaris

United States
Galderma R&D

Completed

Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo

Rosacea

United States
Galderma R&D

Completed

Mirvaso in Use Study

Rosacea

United States
Galderma R&D

Completed

Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States
Galderma R&D

Completed

Non-comparative Evaluation of Facial Expressions Following Lower Face Correction Using Emervel Classic and Emervel Deep

Wrinkles | Nasolabial Folds

Canada
Galderma R&D

Completed

Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis

Psoriasis

United States
Galderma R&D

Completed

Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne

Acne Vulgaris

United States
Galderma R&D

Completed

Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis

Plaque Psoriasis

United States
Galderma R&D

Completed

Repeat Insult Patch Test for Daily Advance Cetaphil Moisturizing Lotion

Skin Irritation

United States
Galderma R&D

Completed

A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV) (DUAL)

Acne Vulgaris

United States, Puerto Rico
Galderma R&D

Completed

Dose Range Study of CD5789 in Acne Vulgaris

Acne Vulgaris

United States
Galderma R&D

Completed

Comparison Dry Foot Skin Between Diabetic and Non-diabetic Subjects and the Effects of Two Cosmetic Foot Care Products

Xerosis Cutis

Germany
Galderma R&D

Completed

Patient-Reported Outcome Of Facial Erythema (PROOF) (PROOF)

Erythema | Rosacea

United Kingdom, Germany, Sweden
Galderma R&D

Completed

Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer (LOOP)

Foot Dermatoses

Germany
Galderma R&D

Completed

Global Management of Facial Rejuvenation With a New Range of Hyaluronic Acid Dermal Fillers (FRESH)

Facial Wrinkles

France, Germany
Galderma R&D

Completed

Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

Rosacea

United States
Galderma R&D

Completed

Comparison of Four Different Regimens of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in Acne Vulgaris (FREE)

Acne

Canada
Galderma R&D

Completed

Treatment of Patients With Blepharitis and Facial Rosacea

Dry Eye | Blepharitis | Meibomianitis

United States
Galderma R&D

Completed

PDT With Metvix® 160 mg/g Cream in Organ Transplant Recipients With Non-melanoma Skin Cancer

Warts | Actinic Keratosis | Basal Cell Carcinoma | Squamous Cell Carcinoma | Bowens Disease

Denmark, Germany, Norway, Sweden, United Kingdom
Galderma R&D

Completed

Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%

Acne Vulgaris

United States
Galderma R&D

Completed

Phase 3 Papulopustular Rosacea Study

Papulopustular Rosacea

United States, Canada
Galderma R&D

Completed

Performance of Different Application Regimens of ACTINICA® on Protection From UVR-induced Erythema After One Day of Sun Exposure in Fair-skinned Healthy Subjects.

Healthy Subjects, Male or Female, of 18-60 Years Old, With Phototype I, II or III, Not Pre-treated/Pre-protected Skin

France
Galderma R&D

Completed

Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%

Erythematous Rosacea

United States
Galderma R&D

Completed

Comparison of Two Botulinum Toxins Type A on Forehead Wrinkles

Wrinkles

Germany
Galderma R&D

Completed

Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

Rosacea

United States, Canada
Galderma R&D

Completed

Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp

Actinic Keratosis

United States
Galderma R&D

Completed

Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance (ACCESS II)

Acne

United States, Canada, Puerto Rico
Galderma R&D

Completed

Adjunctive Usage of a Moisturizing Lotion (Cetaphil® Moisturizing Lotion) to Limit the Skin Irritation Linked to the Set-Up of a Treatment by Topical Retinoid (Differin® Gel 0,1%) in Healthy Subjects of Chinese Origins

Healthy Skin

Singapore
Galderma R&D

Completed

Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%

Acne Vulgaris

United States, Canada
Galderma R&D

Completed

Volume Restoration of Plantar Pad With a Hyaluronic Acid Dermal Filler in Metatarsalgia (ELFE)

Metatarsalgia

France
Galderma R&D

Completed

Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis

Plaque-type Psoriasis

United States
Galderma R&D

Completed

A Multi-Center Study Of CD07743 for the Improvement of Lateral Canthal Lines (CROW'S FEET)

Canthal Lines
Galderma R&D

Completed

Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris

Acne Vulgaris

Canada, United States, Germany, Hungary, Puerto Rico
Galderma R&D

Completed

Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris

Acne Vulgaris

United States, Canada
Galderma R&D

Completed

Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.

Acne Vulgaris

Japan
Galderma Laboratorium GmbH

Completed

Efficacy of Epiduo and Treatment Adherence of Adolescent Patients With Inflammatory Acne (TEENA)

Acne
Galderma Laboratorium GmbH

Completed

Application of Epiduo(R) PUMP in Daily Practice in Patients With Inflammatory Acne (PUMP-it)

Acne Vulgaris
Galderma R&D

Completed

PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Call Carcinoma

Basal Cell Carcinoma

Australia
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, United Kingdom
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

RSV Infection

United States
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Hepatitis C

Belgium, United States, Puerto Rico, Netherlands
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

To Assess the Patients' Ability to Self-Administer Fasinumab (FACT DEVICE)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Alexza Pharmaceuticals, Inc.
Pharmaceutical Research Associates

Unknown

Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder

Agitation,Psychomotor

United States

3

Subscribe